Related Experiment Video
Updated: May 9, 2026
09:33
Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
Published on: July 28, 2013
Molecular neuroimaging in degenerative dementias
J F Jiménez Bonilla1, J M Carril Carril
1Servicio de Medicina Nuclear, Hospital "Marqués de Valdecilla", Universidad de Cantabria, Santander, España. jjimenez@humv.es
Revista Espanola De Medicina Nuclear E Imagen Molecular
|August 13, 2013
Summary
Cerebral amyloid imaging using 11C-PIB PET scans provides valuable insights into Alzheimer's disease progression. This molecular neuroimaging technique aids in early diagnosis and differential diagnosis of dementia.
Area of Science:
- Neuroimaging
- Molecular Biology
- Neurology
Background:
- Structural imaging has limitations in studying cognitive decline.
- Brain perfusion and metabolism imaging (SPECT, PET) offer insights.
- Cerebral amyloid imaging has transformed Alzheimer's disease (AD) diagnostics, viewing it as a continuum.
Purpose of the Study:
- To evaluate the utility of 11C-PIB PET in diagnosing and understanding Alzheimer's disease.
- To explore the role of molecular neuroimaging in cognitive decline.
- To assess amyloid load in preclinical and mild cognitive impairment stages.
Main Methods:
- Utilized Positron Emission Tomography (PET) with the radiotracer 11C-PIB for in vivo imaging.
- Observed specific high brain cortical retention patterns in positive cases.
- Combined 11C-PIB PET with 18F-FDG PET for molecular neuroimaging biomarker assessment.
Main Results:
- 11C-PIB PET demonstrated characteristic retention patterns, distinguishing positive from negative cases.
- Amyloid imaging, especially 11C-PIB PET, is a reference standard for cerebral amyloid detection.
- Clinical application of 11C-PIB PET, alone or with FDG, shows utility in dementia diagnosis.
Conclusions:
- Amyloid imaging is a valuable tool for differential dementia diagnosis.
- 11C-PIB PET aids in early AD diagnosis and evaluating potential treatments.
- 18F labeled radiotracers are being developed due to 11C-PIB's limited availability.
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...